Y16

Research use only, not for human use.

Y16 is a G-protein–coupled Rho GEFs inhibitor; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.

Y16, also known as RhoA-IN-Y16, is a RhoA inhibitor, Y16 blocks the binding of LARG, a DBL-family Rho guanine nucleotide exchange factor, with Rho (Kd = 80 nM). Y16 specifically inhibits LARG catalyzed activation of RhoA and RhoA signaling pathways. Y16 blocks the growth and migration of MCF7 breast cancer cells.

Y16 (10-30 μΜ; 24 hours; NIH 3T3 cells) could inhibit RhoA-GTP formation induced by serum dose dependently and is specific for RhoA.Y16 (10-30 μΜ; 24 hours; NIH 3T3 cells) efficiently inhibits serum or SDF-1α-induced phospho-MLC and phospho-FAK formation, which are downstream of RhoA. Cell Viability Assay Cell Line:NIH 3T3 cells Concentration:10 μΜ, 30 μΜ Incubation Time:24 hours Result:Inhibited RhoA-GTP formation induced by serum dose dependently and was specific for RhoA. Western Blot Analysis Cell Line:NIH 3T3 cells Concentration:10 μΜ, 30 μΜ Incubation Time:24 hours Result:Inhibited serum or SDF-1α-induced phospho-MLC and phospho-FAK formation, which were downstream of RhoA.

——

RhoA-IN-Y16 | Y16

PI3K/Akt/mTOR signaling

mTOR

Rho GEFs

Cancer

——

429653-73-6

384.43

C24H20N2O3

>98% (HPLC)

DMSO : 25 mg/mL 65.03 mM;H2O : < 0.1 mg/mL

Cc1cc(ccc1)COc1cccc(c1)C=C1C(=O)NN(C1=O)c1ccccc1

(E)-4-(3-((3-methylbenzyl)oxy)benzylidene)-1-phenylpyrazolidine-3,5-dione

(-20℃)

With Ice Pack

≥ 2 years